超灵敏毒素检测提高艰难梭菌感染临床特异性并减少过度诊断
该研究纳入298例疑似艰难梭菌感染患者粪便标本,平行进行核酸扩增检测(NAAT)和超灵敏单分子计数毒素A/B检测(Clarity),不一致结果用细胞毒性中和试验(CCNA)验证。结果显示Clarity临床特异性97.4%高于NAAT的89.0%,NAAT+/毒素-患者过度诊断是NAAT+/毒素+的三倍以上,毒素存在与不良结局相关。
要点
- 超灵敏毒素检测临床特异性97.4%,高于NAAT的89.0%。
- NAAT+/毒素-患者过度诊断风险是NAAT+/毒素+的三倍以上。
- 毒素阳性患者CDI复发更常见,提示与不良结局相关。
核心结论
- 超灵敏单分子计数毒素A/B检测在CDI诊断中优于NAAT,可减少过度诊断并提高临床特异性。
- 毒素存在与患者不良结局(如复发)相关。
研究设计与样本
- 前瞻性评估298例疑似CDI患者粪便标本,平行进行NAAT(BD MAX Cdiff或Xpert C. difficile)和Singulex Clarity C. diff toxins A/B检测。
- 不一致结果用细胞毒性中和试验(CCNA)验证,并与疾病严重程度和结局关联分析。
主要发现
- 298例中NAAT阳性64例、阴性234例。
- 32例NAAT+/Clarity-中26例CCNA阴性;4例NAAT-/Clarity+中4例CCNA阴性。
- CDI复发在NAAT+/毒素+患者中比NAAT+/毒素-和NAAT-/毒素-患者更常见。
- Clarity和NAAT的临床特异性分别为97.4%和89.0%。
- NAAT+/毒素-患者过度诊断是NAAT+/毒素+患者的三倍以上。
关键数值与推荐
- Clarity临床特异性97.4%,NAAT临床特异性89.0%。
- 过度诊断在NAAT+/毒素-患者中比NAAT+/毒素+患者常见三倍以上。
临床怎么用
- 在疑似CDI患者中,采用超灵敏毒素检测可提高诊断特异性,减少NAAT阳性但毒素阴性患者的过度诊断。
- 毒素阳性结果提示患者复发风险较高,可辅助临床评估病情和随访。
局限性
- 标本来自298例疑似CDI患者,为单次检测评估,未报告多中心验证。
- 不一致结果仅用CCNA验证,未报告临床随访的完整细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clostridioides difficile infection (CDI) is one of the most common health care-associated infections, resulting in significant morbidity, mortality, and economic burden. Diagnosis of CDI relies on the assessment of clinical presentation and laboratory tests. We evaluated the clinical performance of ultrasensitive single-molecule counting technology for detection of C. difficile toxins A and B. Stool specimens from 298 patients with suspected CDI were tested with the nucleic acid amplification test (NAAT; BD MAX Cdiff assay or Xpert C. difficile assay) and Singulex Clarity C. diff toxins A/B assay. Specimens with discordant results were tested with the cell cytotoxicity neutralization assay (CCNA), and the results were correlated with disease severity and outcome. There were 64 NAAT-positive and 234 NAAT-negative samples. Of the 32 NAAT+/Clarity- and 4 NAAT-/Clarity+ samples, there were 26 CCNA- and 4 CCNA- samples, respectively. CDI relapse was more common in NAAT+/toxin+ patients than in NAAT+/toxin- and NAAT-/toxin- patients. The clinical specificity of Clarity and NAAT was 97.4% and 89.0%, respectively, and overdiagnosis was more than three times more common in NAAT+/toxin- than in NAAT+/toxin+ patients. The Clarity assay was superior to NAATs for the diagnosis of CDI, by reducing overdiagnosis and thereby increasing clinical specificity, and the presence of toxins was associated with negative patient outcomes.
引用
- Sandlund J, Estis J, Katzenbach P, et al. Increased Clinical Specificity with Ultrasensitive Detection of Clostridioides difficile Toxins: Reduction of Overdiagnosis Compared to Nucleic Acid Amplification Tests. J Clin Microbiol. 2019. PMID: 31434726. doi:10.1128/JCM.00945-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。